Silo Pharma Announces Expansion of Intellectual Property Portfolio
February 02, 2023 08:50 ET
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, NJ, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics...
Silo Pharma Announces Stock Repurchase Program
January 31, 2023 07:45 ET
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, NJ, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics...
Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation
January 10, 2023 10:15 ET
|
Silo Pharma, Inc.
Parkinson's disease, bipolar disorder, and chronic pain targeted in study Study aims to support psilocybin as a potential therapeutic for inflammatory disorders ENGLEWOOD CLIFFS,...
Silo Pharma Announces Positive Study Results of SPU- 21 for Arthritis
December 30, 2022 08:10 ET
|
Silo Pharma, Inc.
SPU-21 effective in controlling arthritis progression. SPU-21 Demonstrates Positive Data in Arthritis Suppression using Silo’s Novel Joint Homing Peptide ENGLEWOOD CLIFFS, NJ, Dec. 30, 2022 ...
Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets Combining Traditional Therapeutics with Psychedelic Medicine
December 01, 2022 09:00 ET
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, NJ, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics...
Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tissue
November 21, 2022 07:45 ET
|
Silo Pharma, Inc.
Initial data from study expected in first quarter 2023 ENGLEWOOD CLIFFS, NJ, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage...
Silo Pharma Achieves New Milestone for SP-26 Therapeutic -Initiates IND Enabling Study of Topical Ketamine Formulation
November 11, 2022 08:15 ET
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, NJ, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics...
Silo Pharma to Discuss Mainstream Pharma and Psychedelics at Wonderland Miami Conference
October 26, 2022 09:00 ET
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, NJ, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics...
Silo Pharma Announces Data Supporting Therapeutic Potential of SPC-14 for Alzheimer’s Disease in Pre-Clinical Study
October 20, 2022 08:05 ET
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, NJ, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics...
Silo Pharma extends research pact for Alzheimer’s and Stress Induced Anxiety Therapeutics
October 18, 2022 07:15 ET
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, NJ, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics...